Advances in Cancer Research

Erscheinungsjahr 2015
ISBN: 978-0-12-802920-6
Verlag: William Andrew Publishing

Buch, Englisch, 326 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 730 g

Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics, including taxane-anti-androgens cross-resistance in advanced prostate cancer and proteasome inhibitors in the treatment of multiple myeloma.

Autoren/Hrsg.

Weitere Mitwirkende

Tew, Kenneth D.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung

Inhaltsverzeichnis

1. Unravelling the Complexity and Functions of MTA Coregulators in Human CancerDa-Qiang Li, Rakesh Kumar2. Examination of Epigenetic and other Molecular Factors Associated with mda-9/Syntenin Dysregulation in Cancer Through Integrated Analyses of Public Genomic DatasetsManny D. Bacolod, Swadesh K. Das, Upneet K. Sokhi, Steven Bradley, David A. Fenstermacher, Maurizio Pellecchia, Luni Emdad, Devanand Sarkar and Paul B. Fisher 3. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer Sarah K. Martin and Natasha Kyprianou 4. Stem Cell-Based Therapies for Cancer Deepak Bhere and Khalid Shah5. Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance Nathan G. Dolloff6. Influence of Bone Marrow Microenvironment on Leukemic Stem Cells: Breaking up an Intimate RelationshipPuneet Agarwal and Ravi Bhatia7. Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-negative Breast Cancer: Ligand-mediated Mechanisms of Receptor Regulation and Potential for Clinical TargetingCarly Bess Williams, Adam C. Soloff, Stephen P. Ethier, and Elizabeth S. Yeh8. The Quest for an Effective Treatment for an Intractable Cancer: Established and Novel Therapies for Pancreatic AdenocarcinomaBridget A. Quinn, Nathaniel A. Lee, Timothy P. Kegelman, Praveen Bhoopathi, Luni Emdad, Swadesh K. Das, Maurizio Pellecchia, Devanand Sarkar and Paul B. Fisher

Über Autor(innen)

Tew, Kenneth D.
Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA
The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.